The US pharmaceutical company Pfizer and the German firm BioNTech announced positive results in their initial human trials with the coronavirus vaccine they are working on Wednesday.
The study included 45 adults ages 18 to 55 and tested different doses of the vaccine, which the companies say produced higher antibodies than patients who have recovered from Covid-19.
In a statement, Pfizer’s head of vaccine research and development Kathrin Jansen said the clinical data is positive and that the work is being carried out with the utmost urgency.
The vaccine, according to the note, was generally well tolerated, although in some cases it caused fevers and local pain where it was injected, but without any serious reaction being detected.
The two companies now plan to use the information gathered to conduct a much larger test, with up to 30,000 participants, and which they hope to start in late July if the go-ahead from regulators is received.
Pfizer and BioNTech have submitted data from their first study for peer review and for publication in a scientific journal.
The companies indicated that if the rest of the tests are successful and the vaccine receives regulatory approval, they intend to manufacture up to 100 million doses in the remainder of the year and potentially more than 1.2 billion in 2021.
Shares of Pfizer, a New York-based industry giant, rose sharply on Wall Street on Wednesday following the announcement.
This vaccine is in addition to several others in which other pharmaceutical companies in various countries are working and which have also obtained promising results in the first tests with humans.
Currently, the widespread use of any coronavirus vaccine has not been approved, which has left more than half a million deaths worldwide and more than 10.5 million confirmed cases.
Usually, the period for a vaccine to be available for use at a massive level is at least 12 to 18 months, according to the World Health Organization (WHO), although in this case there is an expectation that the process may speed up.